Fig. 5: Clinical signs and symptoms before and after treatment with tocilizumab. | Nature Communications

Fig. 5: Clinical signs and symptoms before and after treatment with tocilizumab.

From: Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients

Fig. 5

a, b Representative dynamic changes of body temperature in patients with PES. Treated with tocilizumab (a), treated without tocilizumab (b). c Representative images of skin rash from the ear of a PES patient before and after treatment with tocilizumab (similar results were obtained in all patients). d Body temperature of patients with PES before and after treatment with tocilizumab. Paired t test (two-sided) (n = 11, p = 4e-6). e Dynamic changes of neutrophils in PES patients treated with tocilizumab. f The probability of nonrelapse mortality in tocilizumab group and the retrospective group. The probability of nonrelapse mortality was performed by the cumulative incidence of competing events and Gray test. ***p < 0.001. TCZ, tocilizumab. Source data are provided as a Source Data file.

Back to article page